Mode
Text Size
Log in / Sign up

GSTM1 and GSTT1 null genotype frequencies in 300 healthy individuals from urban VenezuelaWhy Your Genes Vary by Region

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note the GSTM1 (38.67%) and GSTT1 (32.67%) null genotype frequencies in this urban Venezuelan cohort.

This cross-sectional descriptive study evaluated the prevalence of GSTM1 and GSTT1 null genotypes among 300 healthy unrelated individuals residing in an urban area of Venezuela. The intervention or exposure involved genotyping for these specific null polymorphisms, with regional and global reference data serving as the comparator context.

The primary outcome measured the frequency of these genetic variants. The study reported a GSTM1 null genotype frequency of 38.67%, a GSTT1 null genotype frequency of 32.67%, and a double null genotype frequency of 6.00%. No secondary outcomes were reported, and no adverse events, serious adverse events, discontinuations, or tolerability data were collected or reported.

Key limitations include the cross-sectional design, which precludes causal inference, and the lack of reported p-values or confidence intervals for the observed frequencies. The study provides an updated genetic baseline for the urban cohort and a descriptive framework for future toxicogenomic research and personalized medicine applications, though it does not inform clinical management of specific conditions.

Imagine you are at a party. Everyone is there to celebrate, but not everyone has the same background. In medicine, we often treat people as if they are all the same. But our genes tell a different story. A new study from Venezuela shows that our DNA changes depending on where we live.

This matters because some drugs work better for some people than others. The reason? It comes down to how your body breaks down chemicals. This process is controlled by specific genes. If your genes are missing a piece, a drug might not work or could cause side effects.

The Surprising Genetic Mix

For years, doctors have known about two specific genes called GSTM1 and GSTT1. These genes help your body flush out toxins and process medicines. Sometimes, a person is born without these genes. Scientists call this a "null" genotype.

Most studies looked at people from one specific place. They found that African, Asian, and European groups had different rates of these missing genes. But what about people in South America? The data was messy and incomplete.

What This Study Changed

Researchers in Venezuela decided to fix this gap. They looked at 300 healthy adults living in an urban area. They tested everyone for these missing genes.

The results were clear. About 39% of the people were missing the GSTM1 gene. Roughly 33% were missing the GSTT1 gene. Even more interesting, about 6% of the group was missing both genes at the same time.

Think of your liver like a busy recycling plant. It takes in bad stuff from food, air, and medicine. It needs special workers to clean it up. GSTM1 and GSTT1 are those workers.

If you are missing a worker, the plant slows down. This is not bad for you right now. But if you take a strong medicine, the cleanup might take too long. The medicine could build up in your blood. This can lead to unexpected reactions.

The Study Snapshot

The team studied 300 unrelated people. They used a simple test called multiplex PCR. This test checks for the presence of the gene pieces. They compared their results to data from around the world.

They found that the Venezuelan group was unique. They did not match the pure African or pure European groups. Instead, they showed a mix of all three. This makes sense because Venezuela has a rich history of mixing different cultures.

The most important finding is the mix. The people in this study had a genetic profile that sits right between West African and Southern European data. This confirms that the population is a blend of many ancestors.

This is not just a number on a page. It means that a drug dose that works for a European patient might need adjustment for a Venezuelan patient. The body processes the drug differently because the genetic workers are different.

But There Is A Catch

This doesn't mean this treatment is available yet.

The study is very important for science. But it does not mean you can go to the pharmacy and get a new drug tomorrow. These findings are a baseline. They are a map for future research.

Doctors need more time to understand how these genes affect specific medicines. They need to run more tests to see exactly which drugs are affected. This process takes years.

You do not need to change your behavior today. You do not need to worry about your genes. Your doctor already considers your health history when prescribing medicine.

However, this news is good for the future. It means medicine will become more personalized. In the future, doctors might test your genes before giving you a strong drug. This will make treatments safer and more effective.

If you have questions about your own health, talk to your doctor. They can explain how your personal history affects your care.

The Limitations

This study has some limits. It only looked at healthy people. It did not include people who are already sick. It also only looked at one city in Venezuela.

Other regions in the country might have different results. The study also only looked at two genes. There are hundreds of other genes that affect how we handle medicine.

Scientists will use this data as a starting point. They will plan new studies to look at sick patients. They will test how these genes affect common drugs like painkillers and antibiotics.

It will take time to get new drugs approved. Safety checks are strict. But this research brings us closer to a future where medicine fits your unique biology. We are moving toward a time when your genes help guide your treatment plan.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
IntroductionThe Glutathione S-Transferase (GST) family consists of enzymes with widely studied genetic polymorphisms. Current documentation of GST variant distribution across Venezuelan regions is fragmented. This study aims to determine the prevalence of GSTM1 and GSTT1 null genotypes in a healthy urban Venezuelan group and to compare these frequencies with regional and global reference data.MethodsA cross-sectional descriptive study was conducted on 300 healthy unrelated individuals. Genotyping was performed via multiplex PCR, and frequencies were calculated based on the presence or absence of specific amplicons.ResultsThe frequencies of the GSTM1 and GSTT1 null genotypes were 38.67% and 32.67%, respectively. The “double null” genotype was observed in 6.00% of the sample, representing a relevant ethnogeographic heterogeneity.DiscussionComparative analysis revealed a divergence from reported data for ancestral Amerindian groups and an allelic distribution pattern reflecting a tri-hybrid genetic architecture intermediate between West African and Southern European references. These findings establish an updated genetic baseline for this urban cohort, highlighting a distinct genotypic distribution within the Venezuelan population. This study underscores the degree of population stratification in the region and provides a descriptive framework for future toxicogenomic research and personalized medicine applications.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.